Actualités Allurion Technologies Inc - ALUR | Actions New York Stock Exchange

Allurion Announces Notification of Issuance of New U.S. Patent on Next-Generation Weight Loss Device for the Treatment of Obesity

Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has...

Allurion Announces Private Placement of Common Stock and Preliminary Unaudited Financial Results for the Fourth Quarter and Fiscal Year 2024

Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has...

Allurion Announces Positive Topline Results From AUDACITY Trial

At 48 weeks, Allurion Balloon subjects had a greater than 50% responder rate and substantially greater weight loss than Control subjects Low rate...

Allurion Technologies, Inc. Announces Reverse Stock Split

Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced that its Board of...

Allurion Announces NYSE Acceptance of Plan to Regain Listing Compliance

Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced that it received an Acceptance Letter from the...

Allurion Launches in the US with its First AI-Native Compounded GLP-1 Program

AllurionMeds is designed to address a critical demand from patients: The Weight Must Stay Off Features Coach Iris, a first-of-its-kind...

Allurion Reports Third Quarter 2024 Financial Results and Provides Business Update

Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced its financial...

Allurion Presents Data From Largest Ever Real-World Experience of 19,428 Patients at The Obesity Society’s Annual Conference

19,428 patients treated with the Allurion Program across 72 countries lost an average of 12.2% of total body weight Allurion Technologies, Inc...

Allurion to Report Third Quarter 2024 Financial Results on November 13, 2024

Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a company dedicated to ending obesity, today announced that it will...

Allurion Announces Submission of First Three Modules of Premarket Approval Application to the U.S. Food and Drug Administration for the Allurion Balloon

Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the submission of the first three modules of its...

Allurion Announces Publication of New Data Demonstrating Muscle Mass Preservation in Patients Experiencing 15% Weight Loss

In a study of 167 patients, average weight reduction was 15.7% at four months, 17.1% at six months, and 14.7% at one year Body fat percentage...

Allurion Announces Publication of Meta-Analysis Demonstrating the Safety and Effectiveness of the Allurion Program for Weight Loss

Systematic review of 11 studies involving 2,107 patients reports average weight reduction of 12.5% with significant improvements in metabolic...

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Allurion Technologies Inc (ALUR)

Outils de qualité professionnelle, pour des investisseurs individuels.

ALUR Actualités

Allurion Announces Notification of Issuance of New U.S. Patent on Next-Generation Weight Loss Device for the Treatment of Obesity

Allurion Announces Private Placement of Common Stock and Preliminary Unaudited Financial Results for the Fourth Quarter and Fiscal Year 2024

Allurion Announces Positive Topline Results From AUDACITY Trial

Allurion Technologies, Inc. Announces Reverse Stock Split

Allurion Announces NYSE Acceptance of Plan to Regain Listing Compliance

Allurion Launches in the US with its First AI-Native Compounded GLP-1 Program

Allurion Reports Third Quarter 2024 Financial Results and Provides Business Update

Allurion Presents Data From Largest Ever Real-World Experience of 19,428 Patients at The Obesity Society’s Annual Conference

Allurion to Report Third Quarter 2024 Financial Results on November 13, 2024

Allurion Announces Submission of First Three Modules of Premarket Approval Application to the U.S. Food and Drug Administration for the Allurion Balloon

Allurion Announces Publication of New Data Demonstrating Muscle Mass Preservation in Patients Experiencing 15% Weight Loss

Allurion Announces Publication of Meta-Analysis Demonstrating the Safety and Effectiveness of the Allurion Program for Weight Loss

Allurion Receives Continued Listing Standards Notice from NYSE

Allurion Announces Publication of New Data Demonstrating Weight Loss in Adolescents Suffering from Obesity

Allurion Announces the Appointment of Eli Lilly Veteran, Keith Johns, to Its Board of Directors

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Allurion Technologies Inc (ALUR) Actualités

Allurion Technologies Inc (ALUR)

Outils de qualité professionnelle, pour des investisseurs individuels.

ALUR Actualités

Allurion Announces Notification of Issuance of New U.S. Patent on Next-Generation Weight Loss Device for the Treatment of Obesity

Allurion Announces Private Placement of Common Stock and Preliminary Unaudited Financial Results for the Fourth Quarter and Fiscal Year 2024

Allurion Announces Positive Topline Results From AUDACITY Trial

Allurion Technologies, Inc. Announces Reverse Stock Split

Allurion Announces NYSE Acceptance of Plan to Regain Listing Compliance

Allurion Launches in the US with its First AI-Native Compounded GLP-1 Program

Allurion Reports Third Quarter 2024 Financial Results and Provides Business Update

Allurion Presents Data From Largest Ever Real-World Experience of 19,428 Patients at The Obesity Society’s Annual Conference

Allurion to Report Third Quarter 2024 Financial Results on November 13, 2024

Allurion Announces Submission of First Three Modules of Premarket Approval Application to the U.S. Food and Drug Administration for the Allurion Balloon

Allurion Announces Publication of New Data Demonstrating Muscle Mass Preservation in Patients Experiencing 15% Weight Loss

Allurion Announces Publication of Meta-Analysis Demonstrating the Safety and Effectiveness of the Allurion Program for Weight Loss

Allurion Receives Continued Listing Standards Notice from NYSE

Allurion Announces Publication of New Data Demonstrating Weight Loss in Adolescents Suffering from Obesity

Allurion Announces the Appointment of Eli Lilly Veteran, Keith Johns, to Its Board of Directors

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application